drivers in HTAs today (scale 1, low to 5, high) were clinical trial design (mean 4.45), right endpoints (mean 4.40), and size …‑relevant endpoints; and a transparent and consistent management of both HTA and regulatory procedures as well as their interface …

towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease … and endpoint selection, were identifed. At the inaugural convention of the European Access Academy dedicated working … fragmented treatment landscape, ii) reasonable number of comparators in PICOs, iii) shape Early Advice so that comparator fulfls …

evolution of other Member States, in the same period, from the perspective of three indicators: access, retention and …